INCB-081776

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameINCB-081776
Drug Alias NameINCB-081776INCB-81776
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTyrosine-protein kinase Mer inhibitors
TargetsAXL receptor tyrosine kinaseTyrosine-protein kinase Mer
Therapy Area/IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Wisconsin-Madison
Inactive CompaniesIncyte Corp
Active IndicationsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A